Parkinson’s Rate Set to Surge, Globally
A new estimate suggests 25.2 million people will be living with Parkinson’s disease worldwide, according to a team of Chinese researchers. That’s an 11.2% increase from 2021 and largely due to population aging, according to their new modeling study, which included data from almost 200 countries.
The greatest rate of the disease is predicted to be in East Asia (10.9 million), followed by South Asia (6.8 million), with the fewest cases expected in Oceania and Australasia.
The researchers say they believe this study provides the first comprehensive projections of the global, regional, and national prevalence of Parkinson’s disease until 2050.
The report was published by The BMJ. In a release, the researchers say these projections “could serve as an aid in promoting health research, informing policy decisions, and allocating resources.”
The Parkinson’s Foundation says nearly 90,000 people in the United States are diagnosed with the disease each year. More than 10 million people worldwide are living with it. The incidence of Parkinson’s disease increases with age, but an estimated 4% of patients are diagnosed before age 50.
The Chinese team used data from the Global Burden of Disease Study 2021 to estimate the age, sex, and year-specific prevalence of Parkinson’s disease in 195 countries and territories from 2022 to 2050.
By 2050, they project cases of Parkinson’s disease will increase in all Global Burden of Disease regions, particularly in moderately developed countries in the middle range of the Socio-Demographic Index (SDI) scale. Their analysis showed the number of people living with Parkinson’s disease in 2050 will be 25.2 million for all ages and both sexes combined, representing a 11.2% increase from 2021.
The researchers believe population aging will be the main driver (89%) behind this rise, followed by population growth (20%), with different patterns at the regional and national levels. They estimate that the all-age prevalence of Parkinson’s disease will reach 267 cases per 100,000 in 2050 (243 for women and 295 for men), an increase of 76% from 2021, while the age-standardized prevalence is expected to rise by 55% to 216 cases per 100,000.
People aged over 80 are predicted to have the highest prevalence (2,087 cases per 100,000) in 2050, while the gap in cases between men and women is also set to widen globally from 1.46 in 2021 to 1.64 in 2050.
Finally, the researchers estimate that increasing physical activity could reduce the future number of Parkinson’s disease cases, whereas stopping smoking may lead to a rise in prevalence, but say these results should be interpreted cautiously.
“An urgent need exists for future research to focus on the development of novel drugs, gene engineering techniques, and cell replacement therapies that are aimed at modifying the course of the disease and improving patients’ quality of life,” the researchers concluded.
In a linked editorial, researchers welcome this study but say adopting more advanced techniques may allow for better forecasting and ensure that healthcare systems, policymakers, and researchers are equipped with reliable data for long-term planning.
“Future projections should prioritize methods that capture the true complexity of chronic disease progression, ultimately leading to more effective interventions and improved patient outcomes,” they wrote.
Join host Jonathan D. Grinstein, PhD, North American Editor for Inside Precision Medicine, as he uncovers the stories behind the pioneers driving the precision medicine revolution.
Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter.
A contributing partner:
Copyright © 2025 Sage Publications or its affiliates, licensors, or contributors. All rights reserved, including those for text and data mining and training of large language models, artificial intelligence technologies, or similar technologies.
Terms of ServicePrivacy Policy
Subscribe to
Inside Precision Medicine Today
FDA Approves Personalized Brain Stimulation Device for Parkinson’s
Ultrasensitive Detection of Protein Aggregates in Neurodegenerative Disease Using Single-Molecule Arrays
Targeting Alzheimer’s Disease By Lowering Oxysterol
Organoid Blood-Brain Barrier Could Improve Neurological Treatments
PODCAST SERIES
RELATED CONTENT
EXPLORE
RELATED SITES
PARTNERSHIPS
We value your privacy
We and our partners process data for the following purposes
Measure audience, Personalised advertising and content, advertising and content measurement, audience research and services development , Precise geolocation data, and identification through device scanning, Storage and access to geolocation information for targeted advertising purposes, Storage and access to geolocation information to carry out marketing studies, Store and/or access information on a device
The Fastest-Growing Brain Disease Is Set to Double – Are We Prepared?
Parkinson’s disease is set to rise dramatically, with cases expected to more than double by 2050, largely due to an aging population.
Researchers predict 25.2 million people will be living with the disease, with the highest numbers in East Asia and South Asia. The surge is most prominent in regions with moderate development, and the gap between men and women affected is widening.
By 2050, an estimated 25.2 million people worldwide will be living with Parkinson’s disease — a 112% increase from 2021 — primarily due to an aging population, according to a new modeling study published today (March 6) in The BMJ.
The study predicts that the overall prevalence of Parkinson’s disease per 100,000 people will rise by 76%, while the age-adjusted prevalence is expected to grow by 55%. The highest rates are projected to be in East Asia.
The researchers say these projections “could serve as an aid in promoting health research, informing policy decisions, and allocating resources.”
Despite being the fastest-growing neurological disorder in terms of both prevalence and disability, future estimates for many countries and regions remain limited.
To address this gap, researchers analyzed data from the 2021 Global Burden of Disease Study, estimating Parkinson’s prevalence based on age, sex, and year across 195 countries and territories from 2022 to 2050.
Globally, they estimate that the number of people living with Parkinson’s disease in 2050 will be 25.2 million for all ages and both sexes combined, representing a 112% increase from 2021.
By 2050, cases of Parkinson’s disease are projected to increase in all Global Burden of Disease regions, particularly in moderately developed countries in the middle range of the Socio-demographic Index (SDI) scale.
The researchers predict that population aging will be the main driver (89%) behind this rise, followed by population growth (20%), with different patterns at the regional and national levels.
They estimate that the all age prevalence of Parkinson’s disease will reach 267 cases per 100,000 in 2050 (243 for women and 295 for men), an increase of 76% from 2021, while the age standardised prevalence is expected to rise by 55% to 216 cases per 100,000.
The largest number of Parkinson’s disease cases is predicted to be in East Asia (10.9 million), followed by South Asia (6.8 million), with the fewest cases in Oceania and Australasia.
The most pronounced increase in Parkinson’s disease cases by 2050 is expected to occur in western Sub-Saharan Africa (292%), while the smallest increases (28%) are projected in central and eastern Europe, due to negative population growth and a smaller contribution from population aging.
People aged over 80 are predicted to have the highest prevalence (2087 cases per 100,000) in 2050, while the gap in cases between men and women is also set to widen globally from 1.46 in 2021 to 1.64 in 2050.
Finally, the researchers estimate that increasing physical activity could reduce the future number of Parkinson’s disease cases, whereas stopping smoking may lead to a rise in prevalence, but say these results should be interpreted cautiously.
As this is a modelling study, it has some important limitations, including low availability and quality of data in some regions, a lack of data on risk factors other than demographics, and being unable to accurately predict the prevalence of Parkinson’s disease in various ethnic groups, or the impact of COVID-19.
However, the researchers say that to the best of their knowledge, this study provides the first comprehensive projections of the global, regional, and national prevalence of Parkinson’s disease until 2050.
“An urgent need exists for future research to focus on the development of novel drugs, gene engineering techniques, and cell replacement therapies that are aimed at modifying the course of the disease and improving patients’ quality of life,” they conclude.
In a linked editorial, researchers welcome this study but say adopting more advanced techniques may allow for better forecasting and ensure that healthcare systems, policy makers, and researchers are equipped with reliable data for long term planning.
“Future projections should prioritise methods that capture the true complexity of chronic disease progression, ultimately leading to more effective interventions and improved patient outcomes,” they conclude.
Reference: “Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021” by Dongning Su, Yusha Cui, Chengzhang He, Peng Yin, Ruhai Bai, Jinqiao Zhu, Joyce S T Lam, Junjiao Zhang, Rui Yan, Xiaoqing Zheng, Jiayi Wu, Dong Zhao, Anxin Wang, Maigeng Zhou and Tao Feng, 5 March 2025, BMJ.
DOI: 10.1136/bmj-2024-080952
Funding: National Nature Science Foundation of China
How does one even prepare for Parkinson’s?
Save my name, email, and website in this browser for the next time I comment.
Subscribe for the Latest in Science & Tech!
We respect your email privacy
